How Tenvie Therapeutics is testing whether neuroinflammation can become the next obesity treatment frontier
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
What Oncolytics Biotech Inc.’s FDA meeting means for pelareorep commercialization
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury
electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
How Cogent Biosciences, Inc.’s bezuclastinib filing could redefine the second-line treatment paradigm in gastrointestinal stromal tumors
Cogent Biosciences files bezuclastinib NDA in second-line GIST. Explore what the PEAK data could change for clinicians, regulators, and investors.
Can Evaxion A/S’s AI-designed polio vaccine concepts reshape the final mile of eradication?
Evaxion A/S unveils AI-designed polio vaccine concepts with eradication potential. Read what this means for vaccine innovation and platform risk.
How Chiesi Global Rare Diseases is positioning lomitapide for earlier lifecycle management in HoFH
CHMP backs paediatric lomitapide for HoFH. Read what this means for clinicians, regulators, and rare disease access across Europe.
Why WINREVAIR’s Phase 2 data matters beyond pulmonary arterial hypertension
CADENCE trial data shows sotatercept’s promise in HFpEF-linked pulmonary hypertension. Find out what this means for treatment and regulation.
What the Hims & Hers Health, Inc. and Novo Nordisk collaboration reveals about the future of obesity drug commercialization
Explore how Hims & Hers and Novo Nordisk are expanding GLP-1 access and what it means for obesity care, pricing, and regulation.